MORINAGA-MILK-INDUSTRY
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, has announced a groundbreaking discovery in the fundamental research of Human-Residential Bifidobacteria (HRB). Through a joint collaboration with Kyoto University, the research has discovered that a specific type of bifidobacteria living in humans, also known as HRB, has the ability to convert precursors of a potentially harmful component into a beneficial metabolite. The research team has uncovered a previously unknown metabolic pathway utilized by the HRB species, converting indole, a potentially harmful compound, into the immunomodulatory metabolite indole-3-lactic acid (ILA). The findings, published in the prestigious journal "Gut Microbes" on May 5, 2024, underscore the unique capabilities of HRB as superior probiotics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240530532346/en/
Human-Residential Bifidobacteria (HRB) strains such as Bifidobacterium longum BB536, B. breve M-16V, B. breve MCC1274, and B. infantis M-63, significantly reduced the concentration of indole produced by Escherichia coli, a known indole producer (Figure 1). Subsequently, the research demonstrated that HRB strains can convert the potentially harmful indole into tryptophan (Trp) and beneficial indole-3-lactate (ILA) (Figure 2). The study also identified a new microbial metabolic pathway involving tryptophan synthase β subunit (TrpB) and aromatic lactate dehydrogenase (ALDH) in the conversion process (Figure 3), highlighting the sophisticated mechanisms by which specific HRB strains contribute to gut health. (Graphic: Business Wire)
Research Background
The research focused on indole, a compound produced by certain intestinal bacteria, which is metabolized in the liver and converted into indoxyl sulfate, a typical urinary toxin. When renal function is impaired, indole and indoxyl sulfate can accumulate in the blood, leading to potential health issues, such as the progression of kidney dysfunction. The formation of indole, which is derived from tryptophan, an essential amino acid for humans, may lead to harmful impacts that are inevitable and pose significant health concerns. In collaboration with Kyoto University, Morinaga Milk’s new research aimed to investigate whether HRB strains could reduce the concentration of indole and transform it into a beneficial metabolite, and understand the underlying mechanism.
Groundbreaking Findings Backed HRB Superiority
- Reduction of Indole Concentration: The study revealed that a specific type of bifidobacteria living in humans, including Morinaga Milk’s HRB strains such as Bifidobacterium longum BB536, B. breve M-16V, B. breve MCC1274, and B. infantis M-63 significantly reduced the concentration of indole produced by Escherichia coli, a known indole producer (Figure 1).
- Conversion of Indole into Tryptophan (Trp) and Indole-3-Lactate (ILA): The research demonstrated that selected bifidobacterial strains, including Morinaga Milk’s HRB strains, can convert indole into tryptophan (Trp) and indole-3-lactate (ILA) (Figure 2). While tryptophan is a necessary amino acid, ILA has been identified as an immunomodulatory compound that supports intestinal and systemic immune health. This discovery marks a significant step forward in understanding how beneficial gut bacteria can transform harmful substances into compounds that promote health.
- Metabolic Pathway Elucidation: The study identified a new microbial metabolic pathway involving tryptophan synthase β subunit (TrpB) and aromatic lactate dehydrogenase (ALDH) in the conversion process (Figure 3). The researchers confirmed that selected bifidobacterial strains, including Morinaga Milk’s HRB strains can efficiently transform exogenous indole into ILA and Trp. This elucidation of the metabolic pathway provides a detailed understanding of the biochemical processes involved, highlighting the sophisticated mechanisms by which bifidobacteria contribute to gut health.
- Exclusive Presence in HRB: An extensive genome database search of 11,943 bacterial strains revealed that the co-occurrence of trpB and aldh genes is exclusive to HRB species. This specificity underlines the unique probiotic potential of these bifidobacteria in human health applications. The genomic analysis underscores the distinctiveness of HRB, positioning them as uniquely capable of performing these beneficial transformations.
Implications for Health
These findings highlight the potential of HRB strains, such as those commercialized by Morinaga Milk, in mitigating the harmful effects of indole by converting it into beneficial ILA. This novel function of bifidobacteria highlights their beneficial effects on human, where indole and its metabolites pose potential adverse health effects for individuals with high risks of chronic kidney disease. Moreover, the conversion of indole into tryptophan and ILA also suggests broader implications for overall gut health. Tryptophan is essential for protein synthesis and serves as a precursor for serotonin, a neurotransmitter that plays a critical role in mood regulation and overall well-being. The production of ILA, with its immunomodulatory properties, further supports the immune system, suggesting the additional health potentials of HRB as probiotics. These findings provide valuable insights into the reasons why HRB species thrive in the human intestinal tract and maintain a symbiotic relationship with the human host.
Continued Commitment to HRB Research
Morinaga Milk Industry remains dedicated to advancing our understanding of HRB and their health benefits. This discovery is a testament to our commitment to innovative research and developing high-quality, scientifically-backed probiotic products that contribute to human health and well-being. Our ongoing research endeavors aim to uncover even more ways in which HRB strains can benefit human health, reinforcing our position as a leader in the field of probiotics.
Embrace the Future: Aim Higher!
Under the Morinaga Milk Group's 10-Year Vision, the company aims to achieve an overseas sales ratio of 15% or more by the fiscal year ending March 2029. The company will continue its effort in developing and providing effective HRB probiotics with a higher level of safety and quality, aiming to strengthen its probiotic sales in the global marketplace to help achieve the goal.
About Morinaga Milk Industry
Morinaga Milk Industry Co., Ltd. is one of the leading dairy product companies in Japan, with over a century of history in harnessing the nutritional properties of dairy products and functional ingredients. Morinaga Milk is also a key global probiotics manufacturer that excels in innovative technology and offers a premium line of probiotics and functional ingredients worldwide. Since the 1960s, Morinaga Milk has been engaged in research on the safety, functional health benefits, and mechanisms of action of probiotic bifidobacteria to better understand their role in maintaining human health. For more information about Morinaga Human-Residential Bifidobacteria (HRB) probiotics, please visit us at https://morinagamilk-ingredients.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240530532346/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
QuantrolOx Unveils VIDYAQAR — the World’s First True Open-Architecture Quantum Platform for Education, Research, Testing and Benchmarking10.12.2025 13:29:00 CET | Press release
QuantrolOx today announced a major milestone in quantum technology with the launch of VIDYAQAR, the world’s first True Open-Architecture Quantum Platform designed specifically for education, research, testing, and benchmarking. The system was unveiled today in India and will be available globally in the first half of 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210668898/en/ VIDYAQAR - A complete quantum platform with cryogenics, control hardware and QPU - powered by Quantum EDGE. The name VIDYAQAR derives from the Sanskrit Vidyākar, meaning “causing wisdom, giving knowledge or science”—a perfect reflection of the platform’s mission to widen access to advanced quantum hardware and accelerate innovation. A Complete, Open and Scalable Quantum Platform VIDYAQAR is a connected, fully open-architecture superconducting quantum system that brings together: CryogenicsControl electronicsQuantum Processing Unit (QPU)Integra
OCTO Revolutionizes Vehicle Safety with AI: Introducing the Proactive and Predictive Anti-Theft System10.12.2025 10:00:00 CET | Press release
Anticipating a theft before it happens. This is the goal of OCTO’s new predictive anti-theft system, developed by the global leader in telematics and data analytics solutions for connected mobility. The new technology combines artificial intelligence, machine learning, and advanced sensors to deliver real-time, personalized vehicle protection capable of recognizing risk signals before a theft event occurs. Drawing on more than 22 years of experience and 610 billion kilometers of driving data, the system transforms the paradigm of vehicle security from reactive to proactive. This approach enables prevention rather than mere response, increasing protection for both private vehicles and corporate fleets. The main features include: Tampering detection: sensors identify attempts to access or remove the devices. Abnormal vehicle movement: the system detects vehicle dragging or lifting while the engine is off. Loss of connection between the devices installed on the vehicle: when one of the tw
Tecnotree Emerges as CX Catalyst Winner for Impact at The Fast Mode Awards 202510.12.2025 09:55:00 CET | Press release
Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, has won the CX Catalyst award for Impact at The Fast Mode Awards 2025. The awards, hosted by leading independent media, research, and analysis platform The Fast Mode, recognises industry visionaries and transformative innovations redefining the global telecoms space. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210927009/en/ Tecnotree Emerges as CX Catalyst Winner for Impact at The Fast Mode Awards 2025 Tecnotree’s award‑winning CX platform delivers omnichannel engagement for operators across voice, SMS, social media, chat, web, and in-app channels. The solution uses AI- and ML-driven analytics to identify customer behaviour, preferences and lifecycle stages — enabling proactive engagement and churn prevention. Real-time personalization and decisioning ensure context-aware interactions, while campaign orchestration unifie
Tyk Marks 10 Years in Business by Proving British Tech Can Grow Responsibly10.12.2025 09:30:00 CET | Press release
Tyk, the independent UK software company powering millions of digital transactions worldwide, is marking its tenth anniversary with B Corp certification - a milestone that recognises a decade of growth built on purpose, not hype. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209886821/en/ Tyk Founders, Martin Buhr (Left), James Hirst (Right) Founded in London in 2014 by Martin Buhr, Tyk began as a one-man side project and has grown into a company of 150 people in 30 countries. Its API management platform now underpins the digital infrastructure of banks, retailers and telcos across more than 100 markets including NatWest, SoundCloud, Zeiss, T-Mobile and Dollar General, powering over 100 million people’s financial transactions daily. From its inception, Tyk has challenged the conventions of the tech industry. It built a profitable business without offices or a “growth at all costs” mentality, long before remote-first work
Sainte Catherine, Institut du Cancer Avignon-Provence (ICAP), Becomes the First Center in Europe to Implement the Varian Latest Halcyon Advancements with Identify integration, PerfectKinetix Dynamic Couch and HyperSight for Personalized Radiotherapy10.12.2025 09:00:00 CET | Press release
Institut du Cancer Avignon-Provence (ICAP), and Varian, a Siemens Healthineers company, announced today the first European installation of the Halcyon version 5.0 radiotherapy platform, combined with IDENTIFY real-time motion management, and the PerfectKinetix Dynamic Couch. This milestone marks a significant step forward in delivering more precise, efficient, and personalized radiotherapy, while enhancing the overall patient experience. The latest evolution of Varian’s Halcyon platform brings together enhanced patient positioning, real-time motion management with IDENTIFY, and embedded high-quality HyperSight imaging. ICAP’s adoption of this ecosystem reflects its commitment to offering patients in the region access to the latest innovations in radiation oncology. Advancing Personalized Care The combination of Halcyon 5.0 and IDENTIFY 5.0 enables clinicians to deliver treatment more effectively by supporting individualized care plans. IDENTIFY* integration is designed to improve posit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
